Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6.14M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
2.26M
-
Shares change
-
-5.12K
-
Total reported value, excl. options
-
$605K
-
Value change
-
-$14.5K
-
Number of buys
-
5
-
Number of sells
-
-3
-
Price
-
$0.27
Significant Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q3 2022
26 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q3 2022.
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.26M shares
of 6.14M outstanding shares and own 36.88% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.03M shares), BlackRock Inc. (258K shares), GEODE CAPITAL MANAGEMENT, LLC (227K shares), PRICE T ROWE ASSOCIATES INC /MD/ (129K shares), STATE STREET CORP (109K shares), COMMONWEALTH EQUITY SERVICES, LLC (90.5K shares), HighMark Wealth Management LLC (80.1K shares), FRANKLIN RESOURCES INC (55.4K shares), Raymond James Financial Services Advisors, Inc. (48.6K shares), and BANK OF AMERICA CORP /DE/ (48K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.